Vesugen

Areas of active research — not promised effects

Each tag links to other compounds with research into that goal. Research use only: these are areas of study, not human-use claims.

Related by research scope · open each to compare

Vesugen holds no FDA-approved New Drug Application and has not been identified on the FDA 503A Category 1 bulk drug substances list permitting compounding with a prescription. It does not appear on the FDA Category-2 restricted substances list that was the subject of the February 2026 HHS action (effective off-Category-2 for ~14 peptides April 23 2026; PCAC review July 23–24 2026, docket FDA-2025-N-6895). Vesugen is therefore not among the approximately seven peptides still under active PCAC Category-2 review (which include BPC-157, TB-500, Semax, Epitalon, and others). It may be sold as a Research Use Only reagent by chemical suppliers for laboratory research, but RUO labelling does not authorise human administration.

Transparent blend · bci-1.0 · never paid-placement

Primary name

Vesugen

Origin

Vesugen (H-Lys-Glu-Asp-OH; KED) is a synthetic tripeptide whose sequence was identified from vascular wall-associated proteins. It belongs to the series of short peptide bioregulators developed at the St. Petersburg Institute of Bioregulation and Gerontology under Professor Vladimir Khavinson. The programme designs tissue-specific, short-sequence peptides intended to act as gene expression modulators in age-related cellular decline. Vesugen's identity is manufacturer/literature-derived; no PubChem entry or standardised registry record has been confirmed (curationStatus: manual_pending).

Registry IDs

PubChem CID

87571363

CAS

204271-66-9

InChIKey

LLSUNJYOSCOOEB-GUBZILKMSA-N

InChIKey

LLSUNJYOSCOOEB-GUBZILKMSA-N

Appearance

White to off-white lyophilised powder (vendor-typical for synthetic tripeptides of this class)

Solubility

Soluble in water; typically reconstituted in sterile water or bacteriostatic wat…

Sequence not available in current seed.

Stability: Tripeptides of this class are susceptible to proteolytic degradation in solution; avoid repeated freeze-thaw cycles. No compound-specific stability data for Ves

Vial sizes

10 mg

Purity grades

≥98% (HPLC, vendor-stated) / ≥99% (HPLC, some vendors)

Salt forms

Free base (primary)

• GHS hazard class on file
• PPE & spill response
• Disposal guidance
• Not-for-human-consumption posture

How much research exists, and of what maturity — never a verdict on whether it works.

Mechanism of action

• Vesugen is proposed to exert vasoprotective activity through epigenetic modulation of gene expression in vascular endothelial cells
• In vitro work demonstrated that Vesugen and the co-tested peptide D-7 stimulated expression of Ki-67, a proliferation-associated nuclear protein whose abundance declines with cellular aging, and that both peptides bound to the promoter region of the MKI67 gene in molecular docking experiments, suggesting direct or indirect transcriptional activation (PMID 25051766)
• A separate tissue-culture study found that Vesugen (Lys-Glu-Asp) specifically stimulated expression of the differentiation factors CXCL12 and WEGC1 in human prostatic fibroblast cultures, with effects more pronounced in aged cultures than in young controls (PMID 22808515)
• In a small uncontrolled human series involving patients with chronic polymorbidity and organic brain syndrome, Vesugen was reported to produce measurable geroprophylactic effects including improved central nervous system functional markers, though the same study also noted prooxidant activity and significant inhibition of haemopoiesis as concerning findings (PMID 26390612)

Pharmacokinetics (ADME)

PK–PD note: No formal pharmacokinetic studies for Vesugen were identified in the retrieved literature. As a tripeptide of approximately 388 Da, rapid proteolytic degradation following systemic administration is e…

Reading the evidence

• Evidence quality and gaps vary by application — see the cited grades above.
• Indexed-article counts span all evidence tiers, not only completed human trials.
• No first-party human-dosing, efficacy, or benefit claims are made here.

Key reviews & evidence-gap sources

• Khavinson V et al. Neuroprotective Effects of Tripeptides—Epigenetic Regulators in Mouse Model of Alzheimer's Disease. Pharmaceuticals (Basel). 2021;14(6):515. — Primary mechanistic + animal (5xFAD mouse) study of KED (Vesugen) and EDR; not a systematic review. Originating Khavinson laboratory.
• Meshchaninov VN et al. Effect of synthetic peptides on aging of patients with chronic polymorbidity and organic brain syndrome. Adv Gerontol. 2015;28(1):62-7. — Small Russian human study (n=32) of vesugen + pinealon; not a registered RCT, no CT.gov registration, results not independently replicated.
• Peptide Science Institute – Vesugen evidence landscape — Aggregator; reports 4 human / 135 animal / 61 reviews within a broad 43,193-item vascular query; states not FDA-approved, no independent Western replication.

No registered human trials found for this compound.

Status

No registered trials found

Summary (literature)

No controlled human safety or tolerability trials for Vesugen were identified. The one available human observational study (PMID 26390612; n=32) reported prooxidant activity and significant inhibition of haemopoiesis alongside potential benefits, representing clinically relevant …

WADA status

Not specifically listed by name on the 2026 WADA Prohibited List. WADA category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) uses broa…

Dominant research route: Oral (capsule) in human clinical reports; intraperitoneal in animal/preclinical models

Human clinical reports (Russian, Khavinson-affiliated): oral KED capsule studied in elderly patients with CNS disorders (memory/attention), in 53 patients (0.2 mg twice daily for one month), and in 32 patients with chronic polymorbidity; also the marketed supplement form in Russia

Bioavailability: No published human pharmacokinetic data; systemic exposure of oral KED in humans has not been characterized. Tripeptides may survive gastrointestinal degradation more readily than longer peptides, but this is theoretical, not measured.

Oral capsule is the dominant route in published human reports. Studies are small, non-randomized, not placebo-controlled, and originate from Khavinson-affiliated investigators; no Western RCT replication exists. Oral-stability ≠ oral-absorption: GI peptidase susceptibility and first-pass metabolism are noted concerns but unquantified for KED.

Animal (mouse): daily intraperitoneal KED administration in 5xFAD transgenic Alzheimer's disease mouse model from age 2–4 months; endpoints assessed after 2 months of daily IP dosing

Bioavailability: IP route bypasses gastrointestinal degradation; used in preclinical mouse model to ensure controlled systemic delivery. No human IP use reported.

The 5xFAD mouse IP study is described as the most methodologically rigorous Vesugen preclinical data. KED prevented dendritic spine loss and modulated AD-related gene expression. No human translation of IP route.

Marketed form (Russia): Vesugen lingual dietary supplement; clinical study referenced in complex therapy of atherosclerosis patients; no standalone PK or controlled trial data for sublingual route identified

Bioavailability: Sublingual route theorized to offer better bioavailability than oral capsules by bypassing GI degradation, but no head-to-head bioavailability studies exist for KED.

Sublingual/lingual form is a commercial Khavinson product line. Clinical evidence is described in product marketing context, not as independent PK characterization. Sublingual absorption is a theoretical advantage for peptide delivery, unquantified for KED.

No published human or animal SC pharmacokinetic study identified; research-chemical injectable conventionally dosed at 100–200 mcg SC, mirroring convention across Khavinson tripeptides

Bioavailability: No human pharmacokinetic study has been published for SC Vesugen. Dosing convention is extrapolated from related Khavinson short peptides, not from KED-specific PK data.

SC route appears in community/research-chemical usage conventions, not in published clinical trials. No registered human clinical trials of Vesugen/KED are listed in trial registries.

No published IM pharmacokinetic or controlled trial data identified; community protocol references 10 mg IM daily for 10 days as a 'standard bioregulator protocol'

Bioavailability: No human pharmacokinetic data published for IM Vesugen. IM convention is community-sourced, not derived from KED-specific clinical pharmacology.

IM route appears in community/aggregator protocols without citation to a primary PK study. Should not be interpreted as a clinically validated administration route.

Animal & human figures are kept visibly separate so studied animal doses are never misread as human guidance.

Sorted A–Z by vendor — never by price

Weekly median $/mg from the live vendor crawl.

Researched storefront prices, bucketed

p25 $2.75 · median $3.00 · p75 $3.15 · 9 researched vendors

Legit, COA-backed band: $2.75–$3.75/mg.

Value rule: don't just buy the cheapest — a price under $3/mg is a red flag. Pair price with COA and independent-test grade.

Estimated cost of research (10 mg)

Vial (best researched price)

$28

Bacteriostatic water (generic estimate)

$6

Syringes / supplies (generic estimate)

$12

What each test proves — general guidance, plus this compound's researched purity data

Purity on the current market (researched)

Vendors universally self-report ≥99% HPLC purity for Vesugen (e.g., American Peptides, Peptide Hackers, Protide Health, Verified Peptides). No independent third-party (Janoshik/MZ Biolabs) test result specific to Vesugen was located in public databases; vendor purity claims are self-attested and not independently confirmed.

Independent labs cited for this compound

No FDA recalls, market withdrawals, or safety alerts specific to Vesugen were found in the sources retrieved. Honest result: none found.

Buyer red-flag checklist

• Not FDA-approved; not evaluated by any Western regulatory agency (FDA, EMA). Approved in Russia only as a supplement, not a drug.
• No registered human clinical trials on ClinicalTrials.gov; evidence is preclinical (animal/cell) and from a single research group (Khavinson/St. Petersburg Institute) with no independent Western replication.
• All vendor purity claims (≥99%) are self-reported; no independent Janoshik/MZ Biolabs COA specific to Vesugen was found in public databases.
• FDA enforcement posture (Import Alert 66-41, Warning Letters to peptide vendors) treats RUO-labeled peptides promoted for human use as unapproved new drugs; RUO disclaimers do not exempt products from FD&C Act scrutiny.
• No human pharmacokinetic data exists; safety profile relies on Russian clinical practice reports without independent Western safety assessment.
• WADA Prohibited List category S0 (non-approved substances) may capture Vesugen for athletes, as it is not approved by any major regulatory body for human use.

GMP vs research-grade: the chemistry (SPPS + HPLC + MS) is identical — the difference is the quality system.

Underdosing / mislabeling: No independent lab test data (Janoshik, MZ Biolabs, Finnrick aggregates) specific to Vesugen underdosing or content failure was found. Janoshik's public peptide testing database did not surface a Vesugen-specific COA. Underdosing prevalence cannot be quantified from available retrieved sources.

• Detention Without Physical Examination of Unapproved New Drugs Promoted In The U.S. Authorizes FDA field divisions to detain without physical examination imported peptide products identified as unapproved new drugs. A 'research use only' label does not create an importation exemption; FDA evaluates actual marketed/intended use. Vesugen is not specifically named on the Red List but falls within scope if promoted for human use. Last revised 19 May 2026.66-41
• An RUO label is not an import exemption — CBP judges actual intended use.
• Lyophilized powder is ambient-stable in transit; temperature control needed for > 7-day transit.
• US-warehouse vendors dodge import scrutiny — they cost more but ship more reliably.

Every item dated & sourced

Not specifically named on the WADA Prohibited List; injectable Vesugen may fall under the S0 'non-approved substances' catch-all for substances not currently approved by any governmental regulatory health authority for human therapeutic use.

No granted patents identified in current seed. Composition-of-matter coverage is limited given the peptide's synthetic origin.

• IACUC / IRB research context
• RUO buyer responsibilities & documentation
• Veterinary / alternative-use where lawful
• Jurisdiction-aware "who may lawfully obtain"

What people discuss

Reported concerns — discussion, not established effects

Reading caveats

• Vendor-affiliated blog/podcast content presenting anecdote as evidence
• Self-experimentation anecdotes dominate; no controlled human trials
• Russian single-research-group (Khavinson) literature cited as efficacy basis
• Small sample, self-selected community reporting

Manually researched from reddit, youtube— theme weights are research estimates, not live counts; aggregated & de-identified. No individual posts, quotes, or usernames are ever shown.

Relative research / market volume — populated once the activity stream is wired

Inline tooltips for lyophilized, RUO, EU/mg, SPPS, 503A and more.

Toggle plain-language ↔ scientific in the header.

• How to read a COA
• Free base vs acetate
• Understanding evidence grades

Khavinson tripeptide Lys-Glu-Asp (KED); studied for vascular endothelial epigenetic regulation and Ki-67 proliferation modulation in preclinical aging models. Approximately 6 articles are indexed (literature last scanned 2026-05-29). US regulatory status: Research Use Only — not FDA-approved; not on 503A/503B compounding lists. Research use only.

Emitted as JSON-LD: ChemicalSubstance · BreadcrumbList · FAQPage.

• Price-drop & back-in-stock alerts
• Regulatory-change email digest
• Print / share this datasheet